Discrepancy between Angina and Ischemia Repeats in Peripheral Artery Disease

Three randomized studies showed exercising significantly improves 6-minute walk outcomes in patients with peripheral artery disease (PAD). However, many participants randomized to exercise did not perceive changes, and sometimes even got worse. 

La discrepancia entre angina e isquemia se repiten en enfermedad periférica

These findings suggest a significant discrepancy between objective and perceived change in walking ability among PAD patients.  

400 patients with peripheral artery disease randomized to exercise (n=205) vs control (n=199) completed a 6-minute walk test and a questionnaire about perceived claudication. Both tests were repeated 6 months after randomization.

Exercising improved significantly 6-minute walking distance almost 40 meters vs. baseline (p<0.001). 

Many patients perceived no improvement in walking ability after 6 months. This was true for the control group, with – 6.5 meters vs baseline (p<0.001), as opposed to the exercise group, which added 26.8 meters (p<0.001).

Another group perceived their situation had significantly worsened vs. baseline. Again, this was true for the control group, with – 27.3 meters, but not for the exercise group, with + 18.4 meters vs. baseline. 


Read also: Abdominal Aortic Aneurysm during the Pandemic: Should They Be Operated or Deferred?


Having set a walking pace, PAD patients will often report no improvement at follow up, which might tilt the scales for revascularization. It seems important to be able to objectively measure walking ability at baseline and follow up to be able to make objective decisions. 

The coronaries have shown angina and ischemia do not walk hand in hand. Now peripheral vascular disease shows similar discrepancy between symptoms and objective test outcomes. 

Conclusion

Exercising significantly improves walking distance in PAD patients. However, many patients do not perceive this change, and some even feel they get worse. 

JAHA-120-017609

Original Title: Perceived Versus Objective Change in Walking Ability in Peripheral Artery Disease: Results from 3 Randomized Clinical Trials of Exercise Therapy.

Reference: Mary M. McDermott et al. J Am Heart Assoc. 2021;10:e017609. DOI: 10.1161/JAHA.120.017609.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...

STRIDE: Semaglutide in Patients with Peripheral Arterial Disease and Type II Diabetes

Peripheral arterial disease (PAD) is a severe complication in patients with type II diabetes, primarily affecting peripheral vessels, especially below-the-knee (BTK) arteries. This condition...

IVUS-Guided vs. Angiography-Guided Drug-Coated Balloon Angioplasty in the Treatment of Femoropopliteal Lesions

Angiography has traditionally been the primary imaging technique for endovascular therapy guidance in patients with peripheral artery disease. However, as it only provides two-dimensional...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

iFR- vs. FFR-Guided Coronary Revascularization: 5-Year Clinical Outcomes

The assessment of coronary stenosis using coronary physiology has become a key tool in guiding revascularization. The two most widely used techniques are fractional...

TAVR in Small Annuli: What Valve Should We Use?

One of the major challenges of severe aortic stenosis are patients with small aortic annuli, defined as ≤430 mm² aortic valve area. This condition...

Patients at High Risk of Bleeding After Coronary Angioplasty: Are Risk Assessment Tools ARC-HBR and PRECISE-DAPT Useful?

Patients undergoing coronary stenting typically receive dual antiplatelet therapy (DAPT) for 6 to 12 months, consisting of a P2Y12 receptor inhibitor and aspirin. While DAPT...